97480-60-9

Usage

Uses

Used in Organic Synthesis:
3,5-DIMETHYLPHENYLTHIOUREA is used as a reagent in organic synthesis for its ability to participate in a variety of chemical reactions, facilitating the creation of new compounds and materials.
Used in Pharmaceutical Research:
In pharmaceutical research, 3,5-DIMETHYLPHENYLTHIOUREA serves as an intermediate, contributing to the development of new drugs by aiding in the synthesis of complex molecules.
Used in Antibacterial Applications:
3,5-DIMETHYLPHENYLTHIOUREA is used as an antibacterial agent, leveraging its potential to inhibit the growth of certain bacteria, thereby offering a means to combat bacterial infections.
Used in Antifungal Applications:
Similarly, it is utilized as an antifungal agent, exhibiting properties that can suppress the growth of fungi, which is beneficial in treating fungal infections.
Used in Dye Production:
3,5-DIMETHYLPHENYLTHIOUREA is used as an intermediate in the production of dyes, highlighting its role in the coloration processes of various materials.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 3,5-DIMETHYLPHENYLTHIOUREA is employed in the manufacturing of drugs, underscoring its importance in the development of medicinal compounds.

InChI:InChI=1/C9H12N2S/c1-6-3-7(2)5-8(4-6)11-9(10)12/h3-5H,1-2H3,(H3,10,11,12)

Upstream product

• 117174-79-5 N-(3,5-dimethylphenylcarbamothioyl)benzamide 
• 108-69-0 3,5-dimethylaminoaniline 
• 1147550-11-5 ammonium thiocyanate 
• 85518-76-9 3,5-dimethylphenylamine hydrochloride 

Downstream Products

• 1056051-17-2 N-(3,5-dimethylphenyl)-4-(4-pyridinyl)-1,3-thiazol-2-amine 
• 73351-87-8 5,7-dimethylbenzo[d]thiazol-2-amine 
• 56979-86-3 (3,5-dimethylphenyl)cyanamide 

Relevant academic research and scientific papers

Design, synthesis and antimicrobial study of novel 1-(1,3-benzothiazol-2-yl)-3-chloro-4H-spiro[azetidine-2,3'-indole]-2',4(1'H)-diones through ketene–imine cycloaddition reaction

The present study deals with the synthesis of novel 1-(1,3-benzothiazol-2-yl)-3-chloro-4H-spiro[azetidine-2,3'-indole]-2',4(1'H)-dione derivatives from the reaction of 3-(1,3-benzothiazol-2-ylimino)-1,3-dihydro-2H-indol-2-one derivatives with chloroacetyl chloride in the presence of triethyl-amine (TEA). The mechanism involved simple acid or base catalysed reaction through the formation of Schiff base followed by cyclisation via ketene–imine cycloaddition reaction. All synthesized compounds were characterized by FT-IR,1H-NMR,13C-NMR, and elemental analysis. The antimicrobial activities of the synthesized derivatives 5a-5g were examined via Micro Broth Dilution method against bacterial strains Bacillius subtilis, Staphylcoccus aureus, E. coli, P. aeruginosa, and fungal strain Candida albicans for determining MIC values. Ampicillin, chloramphenicol, and griseofulvin were used as standard drugs. The MIC values for antimicrobial activity of synthesized compounds were examined using Micro Broth Dilution method. Compounds 5a, 5b, and 5c were found effective against E. coli (MTCC 442) and P.aeruginosa (MTCC 441) and all compounds showed moderate to excellent activity against Streptococcus aureus (MTCC 96) and Bacillius subtilis (MTCC 441). Regarding the antifungal screening, compounds 5a, 5b, and 5c exhibited excellent activity against Candida albicans MTCC 227. 1-(1,3-benzothiazol-2-yl)-3-chloro-4H-spiro[azetidine-2,3'-indole]-2',4(1'H)-dione derivatives may be used as potential lead molecules as effective antimicrobial agents.

Effect of N-1 arylation of monastrol on kinesin Eg5 inhibition in glioma cell lines

An original and focused library of two sets of dihydropyrimidin-2-thiones (DHPMs) substituted with N-1 aryl groups derived from monastrol was designed and synthesized in order to discover a more effective Eg5 ligand than the template. Based on molecular docking studies, four ligands were selected to perform pharmacological investigations against two glioma cell lines. The results led to the discovery of two original compounds, called 20h and 20e, with an anti-proliferative effects, achieving IC50 values of about half that of the IC50 of monastrol in both cell lines. As with monastrol, flow cytometry analyses showed that the 20e and 20h compounds induced cell cycle arrest in the G2/M phase, and immunocytochemistry essays revealed the formation of monopolar spindles due to Eg5 inhibition without any toxicity to Caenorhabditis elegans.

Multicomponent one-pot synthesis of substituted 4h-pyrimido [2,1-b] [1,3] benzothiazole curcumin derivatives and their antimicrobial evaluation

A novel series of ten substituted 4H-pyrimido [2,1-b] [1,3] benzothiazole curcumin derivatives have been synthesized and evaluated for their antimicrobial activity against Gram positive and Gram negative bacteria viz. Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus cereus and against fungi viz. Alternaria solani, Aspergillus niger, Fusarium culmorum and Rhizopus stolonifer. The mechanism involves condensation of substituted benzaldehyde and curcumin via Knovenegal reaction which further reacts with substituted benzothiazole through Michael addition in the presence of pyridine catalyst using methanol as a solvent. The synthesized compounds were analyzed by elemental and spectral analysis.

A PROCESS FOR THE PREPARATION OF THE COMPOUND N-(3,5-DIMETHYLPHENYL)-N'-(2-TRIFLUOROMETHYLPHENYL) GUANIDINE

The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the salt of the compound of formula (II) and a compound of formula (II) with a compound of formula (III), in the presence of a polar organic solvent; a crystalline solid form of the compound of formula (I), in particular crystalline solid form A; to a pharmaceutical composition comprising them; and to their use as a medicament, in particular to the treatment of a condition mediated by Rho-GTPase cell proteins.

OPIOID RECEPTOR MODULATORS AND USE THEREOF

Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method

Synthesis and in vitro Antimicrobial evaluation of Benzothiazole incorporated Thiazolidin-4-ones derivatives

In the course of work on new pharmacologically active antimicrobial agents, we have reported the synthesis of a new class of structurally novel derivatives, incorporating two bioactive structures, a benzothiazole and thiazolidin-4-one, to yield a class of

COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS

Novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cyst

COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering

Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents

Tuberculosis (TB) is one of the deadliest infectious diseases of all times, and its recent resurgence is a supreme matter of concern. Co-infection with HIV and, in particular, the continuous isolation of new resistant strains, makes the discovery of novel anti-TB agents a strategic priority. The research of novel agents should be driven by the accessibility of the synthetic procedure and, in particular, by the lack of cross-resistance with the drugs already marketed. Moreover, in order to shorten the duration of the therapy, and therefore decrease the rate of resistance, these molecules should be active also against the nonreplicating persistent form (NRP-TB) of the infection. The availability of an in-house small library of compounds prompted us to investigate their anti-TB activity. Two compounds, embodying a 2-aminothiazole scaffold, were found to possess a certain inhibitory activity toward Mycobacterium tuberculosis H37Rv, and therefore a medicinal chemistry campaign was initiated in order to increase the activity of the hit compounds and, especially, construct a plausible body of structure-activity relationships. The potency of the hit compound was successfully improved, and, much more importantly, some of the molecules synthesized were found to be active toward the persistent phenotype, and, also, toward a panel of resistant strains. These findings encourage further investigations around this interesting antitubercular chemotype.

4-Pyridylanilinothiazoles that selectively target von Hippel - Lindau deficient renal cell carcinoma cells by inducing autophagic cell death

Renal cell carcinomas (RCC) are refractory to standard therapy with advanced RCC having a poor prognosis; consequently treatment of advanced RCC represents an unmet clinical need. The von Hippel-Lindau (VHL) tumor suppressor gene is mutated or inactivated in a majority of RCCs. We recently identified a 4-pyridyl-2-anilinothiazole (PAT) with selective cytotoxicity against VHL-deficient renal cells mediated by induction of autophagy and increased acidification of autolysosomes. We report exploration of structure-activity relationships (SAR) around this PAT lead. Analogues with substituents on each of the three rings, and various linkers between rings, were synthesized and tested in vitro using paired RCC4 cell lines. A contour map describing the relative spatial contributions of different chemical features to potency illustrates a region, adjacent to the pyridyl ring, with potential for further development. Examples probing this domain validated this approach and may provide the opportunity to develop this novel chemotype as a targeted approach to the treatment of RCC. 2009 American Chemical Society.